Novo Nordisk A/S (NYSE:NVO) Shares Bought by Ingalls & Snyder LLC

Share on StockTwits

Ingalls & Snyder LLC raised its position in Novo Nordisk A/S (NYSE:NVO) by 19.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,318 shares of the company’s stock after acquiring an additional 3,565 shares during the period. Ingalls & Snyder LLC’s holdings in Novo Nordisk A/S were worth $1,292,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Prime Capital Investment Advisors LLC acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth $28,000. Winthrop Partners WNY LLC acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth $28,000. Simon Quick Advisors LLC lifted its stake in shares of Novo Nordisk A/S by 748.6% during the fourth quarter. Simon Quick Advisors LLC now owns 925 shares of the company’s stock worth $54,000 after buying an additional 816 shares during the period. Doyle Wealth Management acquired a new stake in shares of Novo Nordisk A/S during the second quarter worth $57,000. Finally, Pinnacle Bank lifted its stake in shares of Novo Nordisk A/S by 21.7% during the third quarter. Pinnacle Bank now owns 1,140 shares of the company’s stock worth $59,000 after buying an additional 203 shares during the period. Institutional investors own 7.26% of the company’s stock.

NYSE:NVO opened at $62.39 on Thursday. Novo Nordisk A/S has a 12 month low of $46.10 and a 12 month high of $62.69. The firm has a fifty day simple moving average of $57.53 and a 200-day simple moving average of $53.37. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $141.09 billion, a P/E ratio of 24.76, a PEG ratio of 2.20 and a beta of 0.60.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Friday, November 1st. The company reported $0.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. Novo Nordisk A/S had a net margin of 32.44% and a return on equity of 75.48%. The firm had revenue of $4.51 billion during the quarter, compared to analysts’ expectations of $4.55 billion. Equities analysts forecast that Novo Nordisk A/S will post 2.45 EPS for the current year.

Several research firms have recently commented on NVO. Pareto Securities downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Barclays upgraded shares of Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, November 27th. UBS Group downgraded shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Monday, November 18th. Guggenheim downgraded shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Friday, January 3rd. Finally, ValuEngine downgraded shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Tuesday. Two analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $159.65.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Further Reading: What is a stock split?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Abbott Laboratories  Updates FY 2020
Pre-Market Earnings Guidance
Abbott Laboratories Updates FY 2020 Pre-Market Earnings Guidance
Express  Releases Q4 2019
Pre-Market Earnings Guidance
Express Releases Q4 2019 Pre-Market Earnings Guidance
MarineMax  Updates FY20 Earnings Guidance
MarineMax Updates FY20 Earnings Guidance
Squar Milner Financial Services LLC Cuts Position in Invesco BulletShares 2022 Corporate Bond ETF
Squar Milner Financial Services LLC Cuts Position in Invesco BulletShares 2022 Corporate Bond ETF
Vanguard Russell 2000  Stock Position Trimmed by Janney Montgomery Scott LLC
Vanguard Russell 2000 Stock Position Trimmed by Janney Montgomery Scott LLC
Janney Montgomery Scott LLC Has $14.72 Million Stake in L3Harris
Janney Montgomery Scott LLC Has $14.72 Million Stake in L3Harris


 
© 2006-2020 Zolmax.